Skip to main content

Daclizumab Dosage

Applies to the following strengths: 5 mg/mL; 150 mg/mL

Usual Adult Dose for Multiple Sclerosis

17 years and older:
150 mcg subcutaneously once a month

Comments:


Use: For the treatment of adult patients with relapsing forms of multiple sclerosis (MS) who have had an inadequate response to 2 or more drugs

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Precautions

The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for daclizumab. It includes a communication plan, elements to assure safe use, and an implementation system. For additional informationhttp://www.accessdata.fda.gov/scripts/cder/rems/index.cfm

US BOXED WARNINGS:
WARNING: HEPATIC INJURY INCLUDING AUTOIMMUNE HEPATITIS AND OTHER IMMUNE-MEDIATED DISORDERS:


Safety and efficacy have not been established in patients younger than 17 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:

General:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.